Healthcare and Life Sciences

On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.

On March 10, 2026, Elsevier, a global leader in advanced information and decision support and part of RELX, announced it has entered into a definitive agreement to acquire Mytonomy, a leader in video-based patient engagement solutions that will complement Elsevier’s Clinical Solutions portfolio. Cravath is representing RELX in connection with the transaction.

On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.

On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.

Cravath represented the underwriters in connection with the $3 billion registered senior notes offering of Cencora, Inc., a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Proceeds of the offering were used to repay, in full, the term loan facility used to finance Cencora, Inc's acquisition of OneOncology. The transaction closed on February 13, 2026.

Cravath partners Jin‑Kyu Baek, Nicholas A. Dorsey and Lauren Roberta Kennedy were featured in the 2026 edition of “Practice Perspectives: Vault’s Guide to Legal Practice Areas,” which highlights the experiences of practicing lawyers in more than 20 different areas of the law and is published annually.

Cravath partners Andrew C. Finch and Noah Joshua Phillips participated in the American Bar Association’s 2026 Antitrust Spring Meeting, which was held from March 25‑27, 2026, in Washington, D.C. The meeting is a gathering of academics, economists, enforcers and legal service providers, as well as competition, consumer protection and data privacy professionals to share domestic and international perspectives on competition, consumer protection and data privacy law.

On March 24, 2026, Cravath partners Robert I. Townsend III, Michael E. Mariani and Jin‑Kyu Baek were featured as 2026 “Dealmakers of the Year” by The American Lawyer in recognition of their representation of Kenvue in its $48.7 billion acquisition by Kimberly‑Clark. Putting together two companies of their size “is always a complex process,” said Mike. Added Bob, “from the Kenvue perspective, there was definitely a desire to either get to a transaction or pursue one of the other strategic alternatives” the board had considered – “it was a tremendous effort by the entire [Kenvue] management team.”

On February 12, 2026, Cravath partners Elad Roisman, Nicholas A. Dorsey and Sasha Rosenthal‑Larrea were profiled in Lawdragon’s “Lawyer Limelight” series in connection with the Firm’s work for “companies at the forefront of innovation in digital assets, AI, fintech, biotech, media and emerging technologies.”

Cravath partner Margaret T. Segall and of counsel Nicole M. Peles authored a chapter entitled “Navigating the Complex Landscape of Merger Remedies in Dynamic Industries: Insights from Antitrust Authorities” for Global Competition Review’s “Merger Remedies Guide – Sixth Edition,” published on October 31, 2025. The chapter discusses common types of merger remedies, the challenges they face in dynamic industries including the pharmaceutical/biotechnology and technology sectors and the different approaches antitrust authorities use to address them.